UOM.MU AS Latvijas Juras medicinas centrs (MUN) drops 5.73% on volume spike 20 Mar 2026: model sees EUR 9.86

A sharp intraday volume spike pushed UOM.MU stock lower during market hours on 20 Mar 2026, with the price at EUR 7.40, down 5.73% from yesterday. The move came on 9,750 shares traded, a relative volume surge of 43,875.44, as the MUN-listed AS Latvijas Juras medicinas centrs registered heavier selling. We view this as a volume-driven short-term reaction that requires context from valuation, technicals and Meyka AI modelling. Meyka AI provides real-time signals and model-based perspectives to frame the intraday action.

UOM.MU stock: volume spike and intraday move

The main driver today was a volume spike while price fell to EUR 7.40 from a previous close of EUR 7.85. Volume at 9,750 is notable versus the stock’s average reported volume of 0 in the feed, producing a relVolume of 43,875.44. That large relative volume suggests block trades or concentrated selling. During market hours, the one-price trading range was EUR 7.40 to EUR 7.40, indicating fast execution at the new level.

Price action and technicals for UOM.MU stock

UOM.MU trades below the 50-day average of EUR 8.44 but near the 200-day average of EUR 7.08, signaling mixed medium-term momentum. Key indicators show downward pressure: MACD histogram -0.05, ROC -12.43%, and Bollinger Band middle EUR 8.16 with lower band EUR 7.60. The stock’s ATR is EUR 0.06, limiting intraday range. Traders should watch EUR 7.60 and EUR 8.16 as technical support and resistance.

Fundamentals, valuation and sector comparison

AS Latvijas Juras medicinas centrs reports EPS 0.57 and a market cap of EUR 5,920,000 with 800,000 shares outstanding. The feed lists a PE near 12.98 and a price-to-book of 0.94, below the healthcare peer average PE of 28.92. That gap suggests valuation support, but margins are thin with net profit margin 0.0234. Current ratio is 0.86, so liquidity is tighter than many healthcare peers.

Meyka AI rates UOM.MU with a score out of 100

Meyka AI rates UOM.MU with a score out of 100: 71.96 (Grade B+, suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating snapshot shows mixed metric signals, with strength in return on assets and book value, and weaker DCF and debt measures.

Meyka AI’s forecast and price targets for UOM.MU stock

Meyka AI’s forecast model projects a quarterly target EUR 9.86 and a yearly level EUR 9.12. Against the current price of EUR 7.40, the yearly figure implies an upside of 23.24%. Short-term technical support is EUR 7.00 and tactical resistance sits at EUR 8.50. Forecasts are model-based projections and not guarantees. Consider the model alongside liquidity and sector trends.

Risks, catalysts and trading strategy

Catalysts include Latvian healthcare demand, earnings updates, and local regulatory news. Risks include tight liquidity, a small market cap of EUR 5.92M, and limited free float. For volume-spike traders, set tight execution rules: use stop-loss near EUR 6.80 and scale out at incremental targets EUR 8.50 and EUR 9.86. Monitor news and orderbook depth during market hours on MUN.

Final Thoughts

Key takeaways: UOM.MU stock fell 5.73% to EUR 7.40 on a large intraday volume spike during market hours on 20 Mar 2026. Technicals show short-term oversold momentum and a tradeable support band near EUR 7.60. Fundamentals provide valuation support, with PE roughly 12.98 and price-to-book under 1.00, but liquidity and tight current ratio increase risk. Meyka AI’s forecast model projects a yearly level EUR 9.12, implying 23.24% upside from today’s price. Meyka AI assigns a B+ (71.96) grade, reflecting mixed operational metrics but positive model signals. Forecasts are model-based projections and not guarantees. Traders must weigh volume-driven volatility, small market cap dynamics in Germany’s MUN market, and company-level updates before taking positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.